Citeline Scrip Asia 100 Report: The South Korean Clinical Trial Market in 2025 and Beyond
CMIC Group was recently featured in Citeline’s “Scrip Asia 100 Report”. Access the free pdf to read our full featured article.
“The South Korean Clinical Trials Market in 2025 and Beyond: Insights from CMIC’s HyeSook (Aviva) Park”
HyeSook (Aviva) Park, Country Head of CMIC Korea, shares insights on South Korea’s growing role as a premier destination for global clinical research. With a strong regulatory framework, advanced infrastructure, and a skilled workforce, South Korea continues to attract international sponsors seeking high-quality, efficient, patient focused trials. In this Q&A, Park discusses the country’s key advantages, recent regulatory developments, and how CMIC supports sponsors to navigate the Korean market.
Access the full “Scrip Asia 100 Report”:
https://insights.citeline.com/scrip/focus-on-asia/scrip-asia-100/
Copyright ©️ 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company
>> South Korea Services and Locations
>> Clinical Trial Solutions
=============================================================================================================================
